מדינה: אירלנד
שפה: אנגלית
מקור: HPRA (Health Products Regulatory Authority)
VALPROATE SODIUM
Winthrop Pharmaceuticals UK Limited
VALPROATE SODIUM
500 Milligram
Tablets Gastro-Resistant
Withdrawn
2008-01-31
PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Sodium Valproate 500mg Gastro-resistant Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 500mg sodium valproate. Excipient: Amaranth (E123) 0.068 mg. For full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Gastro-resistant tablet Circular, biconvex, lilac-coloured tablets. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS For use in the treatment of epilepsy generalised, partial or other. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Oral. Dosage requirements vary with body weight and age. Sodium valproate tablets may be given twice daily. The tablets should be swallowed whole and not crushed or chewed. _MONOTHERAPY_ ADULTS Dosage should be commenced at 600mg daily in divided doses increasing at 3 day intervals by 200mg daily until control is achieved. The usual dosage range is 1000mg to 2000mg (20-30mg/kg) daily, but where adequate control is not achieved within this range the dose may be further increased to 2500mg per day. CHILDREN OVER 20KG BODY WEIGHT The usual initial dose should be 400mg daily (irrespective of weight) in divided doses with slow increments to the level of adequate control generally between 20 to 30mg/kg body weight daily. Where adequate control is not achieved the dose may be increased to 35mg/kg body weight daily. CHILDREN UNDER 20KG BODY WEIGHT 20mg/kg body weight per day; in severe cases this may be increased but only in patients in whom plasma valproic acid levels can be monitored. Above 40mg/kg/day, clinical chemistry and haematological parameters should be monitored. ELDERLY Although the pharmacokinetics of Sodium Valproate are modified in the elderly, they have limited clinical significance and dosage should be determined by seizure control. T קרא את המסמך השלם